Filing Details
- Accession Number:
- 0001209191-20-027476
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-05-06 16:27:35
- Reporting Period:
- 2020-05-04
- Accepted Time:
- 2020-05-06 16:27:35
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1446372 | M Paul Silva | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Svp & Controller | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-05-04 | 809 | $86.52 | 15,741 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-05-04 | 200 | $259.21 | 15,541 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-05-04 | 250 | $259.97 | 15,291 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-05-04 | 200 | $261.55 | 15,091 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-05-04 | 100 | $262.83 | 14,991 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-05-04 | 59 | $264.75 | 14,932 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-05-04 | 809 | $0.00 | 809 | $86.52 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
2,427 | 2027-02-02 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 169 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $259.21 (range $258.62 to $259.60).
- Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $259.97 (range $259.72 to $260.33).
- Open market sales reported on this line occurred at a weighted average price of $261.55 (range $261.13 to $262.11).
- Open market sales reported on this line occurred at a weighted average price of $262.83 (range $262.74 to $262.92).
- Open market sales reported on this line occurred at a weighted average price of $264.75 (range $264.59 to $264.89).
- The option vests in 16 quarterly installments from 02/03/2017.